Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post on X about a recent paper by Tiantian Wang et al. published in JAMA Oncology:

“Effect of Apatinib Plus Pegylated Lipodox vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant ca ovary: APPROVE trial.

1st chemo-VEGF combo to show PFS and OS in plat resistant ca ovary, increased toxicities a concern.”

“Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer”

Authors: Tiantian Wang et al.

Akhil Santhosh: 1st chemo-VEGF combo to show PFS and OS in platinum-resistant ovarian cancer

More posts featuring Akhil Santhosh.